Table 3.
Clinical and pathological characteristics of sustained responders versus relapsers after end-of-treatment response (ETVR) by univariate analysis.
| Variable | Patients with SVR (n=66) | Relapse after ETVR (n=30) | P value |
|---|---|---|---|
| Age≥40 years | 41 (62.1) | 26 (86.7) | .015 |
| Sex M/F | 42 (63.6)/24 (36.4) | 16 (53.3)/14 (46.7) | .34 |
| BMI≥27 kg/m2 | 34 (51.5) | 13 (46.4) | .87 |
| Diabetes mellitus | 11 (16.7) | 13 (43.3) | .005 |
| Renal impairment | 4 (6.7) | 2 (6.1) | .91 |
| Previous interferon | 17 (25.8) | 16 (53.3) | .008 |
| Alcohol intake | 1 (1.5) | 1 (3.3) | .56 |
| Organ transplant | 5 (7.6) | 4 (13.3) | .37 |
| HBV or HIV coinfection | 9 (13.6) | 4 (13.3) | .99 |
| Hemophilia | 0 (0.0) | 1 (3.3) | .14 |
| Overlap syndromea | 7 (10.6) | 0 (0.0) | .064 |
| Inflammation gradeb | |||
| 0-2 | 37 (80.4) | 19 (73.1) | .471 |
| 3-4 | 9 (19.6) | 7 (26.9) | |
| Fibrosis stageb | |||
| 0-2 | 33 (71.7) | 16 (61.5) | .373 |
| 3-4 | 13 (28.3) | 10 (38.5) | |
| EVRc | 58 (95.1) | 26 (86.7) | .157 |
Data are expressed as n (%). NS; not significant, INF; interferon. EVR; early virological response. SVR; sustained virological response.
a
Means detection of ≥1autoantibody in serum.
b
Liver biopsy done in 72 patients of the 96 who completed the treatment, 46 in the SVR group and 26 of those who had virological relapse after ETVR.
c
PCR at 12 weeks post-treatment was done in 91 patients of the 96 who completed the treatment, 61 in the SVR group and all the 30 who had virological relapse after ETVR.